Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

The Lancet

Volumn 378, Issue 9787, 2011, Pages 238-246

  Molina, Jean Michel ^a   Cahn, Pedro ^b   Grinsztejn, Beatriz ^c   Lazzarin, Adriano ^d   Mills, Anthony ^e   Saag, Michael ^f   Supparatpinyo, Khuanchai ^g   Walmsley, Sharon ^h   Crauwels, Herta ⁱ   Rimsky, Laurence T ⁱ   Vanveggel, Simon ⁱ   Boven, Katia ^j  

^a SAINT LOUIS HOSPITAL   (France)

^b FUNDACIÓN HUÉSPED   (Argentina)

^c Funda??o Oswaldo Cruz   (Brazil)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e Anthony Mills MD Inc   (United States)

^f University of Alabama at Birmingham   (United States)

^g CHIANG MAI UNIVERSITY   (Thailand)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ TIBOTEC BVBA   (Belgium)

^j Tibotec Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL FUMARATE PLUS RILPIVIRINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS LOAD;

EID: 79960381844     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60936-7     Document Type: Article

References (36)

1. DHHS Panel on Antiretroviral Guidelines for Adult and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - January 10, 2011 http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (accessed May 5, 2011).
2. MA Thompson, JA Aberg, P Cahn et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society - USA Panel JAMA 304 2010 321 333
3. BG Gazzard, J Anderson, A Babiker et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 HIV Med 9 2008 563 608
4. N Clumeck, A Pozniak, F Raffi EACS Executive Committee European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults HIV Med 9 2008 65 71 (Pubitemid 351228129)
5. JA Pérez-Molina Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients HIV Clin Trials 3 2002 279 286
6. Bristol-Myers Squibb FDA label for efavirenz capsules and tablets - November, 2010 http://packageinserts.bms.com/pi/pi-sustiva.pdf (accessed May 5, 2011).
7. Tibotec FDA label for rilpivirine tablets - May, 2011 www.accessdata.fda.gov/drugsatfda-docs/label/2011/202022s000lbl.pdf (accessed May 28, 2011).
8. Desmidt M, Willems B, Dom P, et al. Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278. 12th European AIDS Conference; Cologne, Germany; Nov 11-14, 2009. Abstract PE7.1/4.
9. AL Pozniak, J Morales-Ramirez, E Katabira et al. Efficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: week 96 results of a phase IIb randomized trial AIDS 24 2010 55 65
10. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. TMC278 shows favorable tolerability and non-inferior efficacy compared to efavirenz over 192 weeks in HIV-1-infected treatment-naïve patients. 19th Annual Canadian Conference on HIV/AIDS Research; Saskatoon, Canada; May 13-16, 2010. Abstract 7214.
11. Vanveggel S, Buelens A, Crauwels HM, et al. TMC278 25 mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers.12th European AIDS Conference; Cologne, Germany; Nov 11-14, 2009. Abstract PE7.1/2.
12. Vanveggel S, Buelens A, Crauwels HM, et al. TMC278 25mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers. 47th Annual Meeting of the Infectious Diseases Society of America; Philadelphia, PA, USA; Oct 29-Nov 1, 2009. Abstract 1620.
13. L Tambuyzer, H Azijn, LT Rimsky et al. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors Antivir Ther 14 2009 103 109
14. CJ Cohen, J Andrade-Villanueva, B Clotet et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial Lancet 377 2011 229 237
15. Center for Drug Evaluation and Research Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval 2002 US Food and Drug Administration Silver Spring, MD
16. NIAID. Division of AIDS table for grading the severity of adult and pediatric adverse events - version 1. Dec 28, 2004.
17. AS Levey, JP Bosch, JB Breyer Lewis, T Greene, N Rogers, D Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
18. R Manfredi, L Calza, F Chiodo Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study J Acquir Immune Defic Syndr 35 2004 492 502 (Pubitemid 38420658)
19. RM Gulick, HJ Ribaudo, CM Shikuma et al. Triple-nucleoside regimens versus efavirenz-containing regiments for the initial treatment of HIV-1 infections N Engl J Med 350 2004 1850 1861 (Pubitemid 38917251)
20. F Pulido, JR Arribas, JM Miró et al. Clinical, virological and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naïve subjects with advanced HIV infection J Acquir Immune Defic Syndr 35 2004 343 350 (Pubitemid 38332794)
21. R van Leeuwen, C Katlama, RL Murphy et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected subjects AIDS 17 2003 987 999 (Pubitemid 36549710)
22. I Suarez Lozano, M Garrido, P Viciana et al. How ART works in naive subjects in clinical practice: ACTG 384 was mimicked in an observational database (Spanish VACH Cohort) Antivir Ther 8 suppl 1 2003 337
23. F Van Leth, P Phanuphak, K Ruxrungtham et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study Lancet 363 2004 1253 1263 (Pubitemid 38496486)
24. JE Gallant, E Dejesus, JR Arribas et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV N Engl J Med 354 2006 251 260 (Pubitemid 43113030)
25. VA Johnson, F Brun-Vézinet, B Clotet et al. Update of the drug resistance mutations in HIV-1: December 2009 Top HIV Med 17 2009 138 145
26. JL Lennox, E DeJesus, A Lazzarin et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
27. J Adams, N Patel, N Mankaryous, M Tadros, CD Miller Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents Ann Pharmacother 44 2010 157 165
28. Rimsky L, Eron J, Clotet B, et al. Characterization of the resistance profile of TMC278: 48-week analysis of the Phase III studies ECHO and THRIVE. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA, USA; Sept 12-15; 2010. Abstract H-1810.
29. NA Margot, JM Waters, MD Miller In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine Antimicrob Agents Chemother 50 2006 4087 4095 (Pubitemid 44865153)
30. LC Mbuagbaw, JH Irlam, A Spaulding, GW Rutherford, N Siegfried Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals Cochrane Database Syst Rev 8 2010 CD004246.
31. OF Laterza, CP Price, MG Scott Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48 2002 699 707 (Pubitemid 34439101)
32. Hoetelmans R, Kestens D, Stevens M, et al. Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV; Québec City, QC, Canada; April 28-30, 2005. Poster 2.11.
33. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race analyses on week 48 safety and efficacy findings in treatment-naïve, HIV-1-infected patients enrolled in ECHO and THRIVE. 48th Annual Meeting of the Infectious Diseases Society of America; Vancouver, BC, Canada; Oct 21-24, 2010. Abstract 1124.
34. M Nelson, G Amaya, N Clumeck et al. Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials J Int AIDS Soc 13 suppl 4 2010 P210
35. Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J. Prevalence of genotypic and phenotypic susceptibility to etravirine in US samples received for routine resistance testing. 18th International AIDS Conference; Vienna, Austria; July 18-23, 2010. Abstract MOPDB105.
36. Mathias AA, Menning M, Wei X, Dave A, Chuck S, Kearney BP. Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF. 18th International AIDS Conference; Vienna, Austria; July 18-23, 2010. Abstract LBPE17.